Buspirone for Opioid Tapering

• Status: Completed
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces symptoms of opioid withdrawal among patients undergoing a clinically-indicated and supervised taper from their opioid pain medications. This is premised on strong preclinical scientific support but has not yet be well-examined in humans.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Buspirone

Criteria

Inclusion Criteria:

• Be at least 18 years old

• Be undergoing taper of prescribed opioid pain medications at the study site

Exclusion Criteria:

• Being pregnant or breastfeeding

• Past 7-day use of grapefruit juice or other strong Cytochrome (CYP) P450 inhibitors or inducers

• Have medical or psychiatric condition that is contraindicated with buspirone administration

• Current suicidality as assessed by clinic staff or the Columbia Suicide Severity Rating Scale